SCHEMBL6287931

SCHEMBL6287931

COc1ccc(N2CCN(C(=O)Nc3ncc(C(C)C)s3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
MAPT P10636 8/20 0.54
LMNA P02545 3/20 0.52
ALDH1A1 P00352 2/20 0.52
TP53 P04637 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
MAPK1 P28482 1/20 0.51
PKM P14618 1/20 0.51
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
PTPN7 P35236 1/20 0.50
CCNE1 P24864 2/20 0.49
CDK2 P24941 2/20 0.49
CDK5 Q00535 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
GFER P55789 1/20 0.48
DGAT1 O75907 1/20 0.47
HTR1A P08908 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285598 0.87 PANK3 (0.58) KMT2AMAPTALDH1A1PKMCA12
SCHEMBL6285286 0.86 MAPT (0.59) KMT2AMAPTLMNAALDH1A1TP53
SCHEMBL27570633 0.79 CDK2 (0.61) KMT2AALDH1A1CCNE1CDK2CDK5
SCHEMBL6282734 0.79 CDK2 (0.61) KMT2AALDH1A1CCNE1CDK2CDK5
SCHEMBL6286715 0.79 CCNE1 (0.54) KMT2AMAPTLMNAALDH1A1MAPK1
SCHEMBL6284830 0.78 CDK2 (0.59) KMT2ALMNAALDH1A1PKMCCNE1
SCHEMBL5835991 0.76 CCNE1 (0.71) KMT2ATP53CCNE1CDK2CDK5
SCHEMBL13234920 0.75 MAPT (0.87) KMT2AMAPTLMNAALDH1A1TP53
SCHEMBL6286647 0.75 CDK2 (0.58) ALDH1A1CCNE1CDK2CDK5SMN1; SMN2
SCHEMBL6283718 0.75 CDK2 (0.72) KMT2AMAPTLMNAALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-20190330167-A1 ACTIVATORS OF HIV LATENCY THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2019-10-31 US disclosed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330167-A1 ACTIVATORS OF HIV LATENCY NFATC1, EP300, CD69 KMT2A 535/4885MAPT 2314/4885LMNA 1695/4885
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 KMT2A 2751/4885MAPT 3745/4885LMNA 1246/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 KMT2A 2751/4885MAPT 3745/4885LMNA 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.